Skip to main content
Springer logoLink to Springer
. 2025 Dec 23;67(4):1029–1037. doi: 10.1007/s13353-025-01039-2

Polymorphism of the HMGA2 gene in Polish children and adolescents with short stature and diverse growth hormone secretion

Katarzyna Anna Majewska 1,✉, Marta Kaczmarek-Ryś 2, Justyna Hoppe-Gołębiewska 2, Joanna Nowacka-Woszuk 3, Magdalena Prauzińska 4, Jarosław Szydłowski 4, Monika Naskręcka 5, Andrzej Kędzia 1, Andrzej Pławski 6,7
PMCID: PMC13745402  PMID: 41432898

Abstract

HMGA2 is one of the common genes strongly associated with adult and childhood height. Some studies have also linked this gene to growth hormone deficiency (GHD). This study aimed to investigate polymorphic variants of the HMGA2 gene in Polish children and adolescents with short stature and GHD. Study cohort consisted of 157 children with short stature, including 111 with GHD and 46 with normal growth hormone (GH) secretion. The control group consisted of 142 healthy children of normal height. High-resolution melting (HRM) was used to screen for sequence variants and Sanger sequencing was performed to identify the detected changes. No variants were identified in the coding sequence of the HMGA2 gene. However, two known polymorphisms were observed in intron 3: the G insertion (rs3834468) and the T > A substitution (rs73115423). The statistical analysis of these allele frequencies comparing all short stature children versus controls revealed no significant differences for both polymorphisms studied. However, for rs73115423 within the short stature group, children with GHD had over 3 times lower. A allele frequency than those with normal GH secretion, and the difference was statistically significant (p = 0.042). For rs3834468 no differences were identified within the short stature group. Our findings do not support a definitive role of HMGA2 in the pathogenesis of short stature in Polish children and adolescents. However, they highlight a potential involvement of this gene in the complex mechanisms regulating the somatotropic axis, particularly in relation to GH secretion.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s13353-025-01039-2.

Keywords: HMGA2 gene, Polymorphism, Short stature, Growth hormone deficiency, Children

Introduction

Human height is a highly polygenic trait. The additive genetic contribution to its normal variation has been estimated to be approximately 80–90%. In addition to complex polygenic inheritance, many monogenic defects in genes encoding proteins with functions essential for the proper growth process have been described (Wit et al. 2019; Weedon et al. 2007, 2008; Grant et al. 2008; Bicknell et al. 2025). Although severe mutations in specific genes are related to rare syndromes with extreme stature, they do not explain the causes of height variation across the whole population (Weedon et al. 2007). It seems that thousands of common variants contribute to height determination in humans, and their combined contribution has a substantial effect on stature, while individual effect sizes are small (Bicknell et al. 2025). However, genetic variation is not a definite determinant, as deprivation, comorbidity, malnutrition or other environmental factors may disturb this polygenic inheritance model (Bicknell et al. 2025; Fusco et al. 2016). Various clinical conditions, such as abnormal intrauterine development, chronic systemic diseases, or intestinal malabsorption, can delay and restrict the growth process in children. Short stature may also be a part of genetic syndromes, such as Turner’s, Down’s, or Prader-Willi’s. In some children, apparently healthy, with no coexisting diseases, growth retardation may result from a malfunction of the growth hormone (GH) and insulin-like growth factor 1 (IGF1) axis, where the most common diagnosis is growth hormone deficiency (GHD) (Bang 2024; Grunauer and Jorge 2018; Majewska et al. 2024).

Studies that aimed to reveal the genetics of height determination were initially focused on short stature. Many candidate genes were identified, but fewer of them were reproducibly associated with height variation (Hendriks et al. 2011). Although numerous monogenic defects in genes involved in proper GH secretion and action have been related to growth disorders, genome-wide association studies (GWAS) have indicated that only a minority of genes related to adult height are directly associated with GH-IGF1 axis, while the majority of them seem to act through different pathways (Wit et al. 2019). Therefore, studies on other candidate genes are needed to advance our understanding of short stature and growth hormone deficiency pathogenesis.

Among the genes affecting growth variation, those involved in cell cycle regulation have also been described. One of them is the high-mobility group A2 (HMGA2) gene. In the GWAS performed by Weedon et al., HMGA2 was the first common gene appearing to be strongly associated with adult and childhood height (Weedon et al. 2007; Hendriks et al. 2011). Thereafter, common variants within this gene have been repeatedly associated with height determination in multiple studies of various populations from different geographical regions and also across species (Fusco et al. 2016). Some studies have also related the HMGA2 gene with GHD (Gorbenko del Blanco et al. 2011). Our study aimed to investigate the polymorphic variants of the HMGA2 gene in a cohort of Polish children and adolescents with short stature and growth hormone deficiency (GHD). To the best of our knowledge, no prior studies have examined HMGA2 gene polymorphisms in the context of growth failure within the Polish pediatric population.

Materials and methods

The study cohort included 157 children with short stature (115 boys and 42 girls) aged from 4 to 17 years (mean ± SD: 9.55 ± 3.28 years), patients of Karol Jonscher Memorial Hospital of Poznan University of Medical Sciences. Inclusion criteria covered height SDS (hSDS, standard deviation score of child height in relation to age and gender) below − 2 and completion of diagnostic tests evaluating the causes of short stature. Exclusion criteria comprised of accompanying chronic diseases other than GHD, such as malabsorption, genetic syndromes, organ failure, as well as mental retardation. Patients were divided into groups based on the peak GH serum concentration (DIAsource hGH-IRMA): those with GH < 10 ng/ml were diagnosed with GHD according to Polish standards (111 children) and those with peak GH level ≥ 10 ng/ml were classified as having normal GH secretion (46 children) (Majewska et al. 2024; Binder et al. 2019; Oświęcimska et al. 2016). For more detailed analysis, patients with GHD were further divided into subgroups of those with GH peak level < 5 ng/ml (36 children) and ≥ 5 < 10 ng/ml (75 children). Additional information collected on patients also included the growth velocity in the first year of recombinant human growth hormone (rhGH) therapy in those children who were treated with somatropin (Omnitrope or Genotropin at a dose of 0.170–0.180 mg/kg of body weight/week, administered in daily subcutaneous injections).

The control cohort included 142 children, of whom 79 were boys, and 63 were girls, aged 3 to 17 years (mean ± SD: 8.93 ± 4.04 years) and admitted to the hospital for diagnostic or therapeutic purposes, in particular due to routine otolaryngological procedures such as adenoidectomy or tonsillectomy, or acute infections. The inclusion criteria for the control group comprised of normal height and normal development, while the exclusion criteria covered known systemic chronic diseases, developmental retardation, genetic syndromes or established diseases of possible genetic origin, and any other pathologies related to growth disturbances. Healthy children from the control group were not subject to GH stimulation tests.

All participants underwent physical examinations, with the exact measurements of height, and assessment of general health. Height measurements were made in centimeters (cm) with an accuracy of 1 mm (mm), performed using a stadiometer. Based on the collected data, for all participants, appropriate hSDS values were calculated according to the guidelines and general population data (Palczewska and Niedźwiedzka 2001; Kułaga et al. 2011 and 2013).

Individuals included in both cohorts came from the same geographical region (central and western Poland), were attending public schools or kindergartens, and were under the care of public health services, therefore their socioeconomic status can be considered as similar.

Molecular analysis

DNA was extracted from peripheral blood leukocytes using the QIAamp DNA Blood Mini kit (Qiagen) according to the manufacturer’s protocol. Isolates were diluted to 50 ng/µl and stored at 4 °C until use.

High-resolution melting analysis (HRM) was used to screen for sequence variants in the HMGA2 gene, and Sanger sequencing was performed to confirm and identify the detected changes. Primer3Plus Online Software (version: 3.3.0) was applied to design the primers (Untergasser et al. 2012). Primers’ sequences are listed in Supplementary material (Suppl. 1).

HRM was performed using the Rotor-Gene Q thermocycler (Qiagen, Hilden, Germany) in a final volume of 16 µL. The reaction mixture contained 8 µL of 2× HRM PCR Master Mix (Type-it HRM PCR Kit, Qiagen), 50 ng of DNA template, 1 µL of each primer (5 pmol/µL), and 5 µL of PCR-grade water. The DNA fragments were amplified using real-time PCR, which involved an initial denaturation at 95 °C for 5 min, followed by 40 cycles as follows: 95 °C for 10 s, 55 °C for 30 s, and 72 °C for 10 s. To determine the melting points, a melting curve analysis was performed by slowly increasing the temperature from 65 °C to 90 °C in 0.1 °C increments. The melting curves were further analyzed using the Rotor-Gene Q Series software version 2.3.4 (Qiagen).

Sanger sequencing was applied to identify sequence variants in samples with different melting profiles. The commercial BigDye™ Terminator v3.1 Cycle Sequencing Kit, and the SeqStudio™ Genetic Analyzer System (Thermo Fisher Scientific, Waltham, MA USA) were used according to manufacturer procedures.

Statistical analysis

Statistical analyses were conducted using IBM SPSS Statistics version 28. The significance level was set at 0.05. The Shapiro–Wilk test was used to assess the normality of data distributions. Due to the lack of normal distribution, nonparametric tests were applied. The Mann–Whitney U test was used to compare quantitative data between two groups. To examine associations between categorical variables, the chi-square test was employed. Additionally, odds ratios (https://www.medcalc.org/calc/odds_ratio.php) and their p-values were calculated to assess the strength and significance of associations between selected categorical variables.

The study was conducted following the guidelines of the Helsinki Declaration. Its protocol was approved by the local Ethics Committee at Poznan University of Medical Sciences (No. 1070/15). Legal guardians of all the participants gave their informed consent.

Results

Clinical characteristics of the studied cohorts, including age, hSDS, and growth velocity are presented in Table 1.

Table 1.

Clinical characteristics of the studied cohorts

Parameter
(mean ± S.D.)
Children with short stature
n = 157
Control group
n = 142

Boys

n = 115

Girls

n = 42

Together

n = 157

Boys

n = 79

Girls

n = 63

Together

n = 142

Age [years] 9.72 ± 3.42 9.09 ± 2.85 9.55 ± 3.28 8.85 ± 3.96 9.04 ± 4.17 8.93 ± 4.04
hSDS −2.81 ± 0.68 −2.75 ± 0.74 −2.79 ± 0.69 0.41 ± 0.99 0.12 ± 0.89 0.28 ± 0.95
Growth velocity* [cm/year] 8.87 ± 1.25 9.16 ± 1.42 8.94 ± 1.29 - - -

hSDS, height standard deviation score; Growth velocity, height increment in centimeters during in the first year of rhGH treatment; *data available for 89 patients

The differences in melting curves in HRM analysis were observed for one studied amplicon covering exon 3 of the HMGA2 gene with intronic boundaries. All samples showing differences were selected for Sanger sequencing to determine the genotypes. When compared to the genomic reference sequence (GRCh38.p14), two known polymorphisms in intron 3 were identified: the G insertion (rs3834468, NM_003483.6: c.249 + 34_249 + 35insG, genomic position 12:g.65838603_65838604insG) – Fig. 1 and the T > A substitution (rs73115423, NM_003483.6: c.249 +6 T> A, genomic position: 12:g.65838575T > A) – Fig. 2.

Fig. 1.

Fig. 1

Chromatograms for G insertion within intron 3 of the HMGA2 gene (rs3834468). All three genotypes are presented

Fig. 2.

Fig. 2

Chromatograms for T > A polymorphism within intron 3 of the HMGA2 gene (rs73115423). Two identified genotypes are presented

The statistical analysis of the allele frequencies was performed for various comparisons. First, we compared all short stature children versus controls, and no significant differences in allele frequencies were found for either of the two polymorphisms studied (rs3834468 and rs73115423).

Next, allele frequencies were compared between controls and patients divided into subgroups based on the peak GH level (GH < 10 ng/ml; n = 111 and GH ≥ 10 ng/ml; n = 46), as well as between the two segregated subgroups of GHD patients. We found that for rs73115423 (T > A), subjects with GH < 10 ng/ml differed significantly from patients with GH ≥ 10 ng/ml (p-value = 0.0424) with an over three times higher A allele frequency in a group with normal GH secretion (A allele frequency 0.0652 versus 0.0180 for patients with GHD). Detailed results are presented in Table 2. Additional analysis using segregation of patients with severe GHD (GH < 5 ng/ml, n = 36) and moderate GHD (GH ≥ 5 < 10 ng/ml, n = 75) also revealed a significant difference (p-value = 0.0473) between patients with GH ≥ 5 < 10 and those with GH ≥ 10 ng/ml, while the difference between GH < 5 and GH ≥ 10 ng/ml did not reach the statistical significance. For the second analyzed polymorphism, there were no significant differences in any of the performed comarisons. Detailed results are presented in Supplementary material (Suppl.2).

Table 2.

Allele frequencies in studied cohorts, with calculated odds ratios and p-values for comparisons between groups

variant Groups
rs3834468 genotypes

1

all patients (n = 157)

2

patients with GH < 10 ng/ml (n = 111)

3

patients with GH ≥ 10 ng/ml (n = 46)

4

controls

(n = 142)

[-/-] 148 105 43 138
[-/insG] 8 6 2 4
[insG/insG] 1 0 1 0
[-] frequency 0.9682 0.9730 0.9565 0.9859
[insG] frequency 0.0318 0.0270 0.0435 0.0141
Odds ratio test results – comparisons between studied groups
1 versus 4 2 versus 4 3 versus 4 2 versus 3
p-value 0.1627 0.3076 0.1068 0.4540
Odds ratio value 0.4343 0.5143 0.3143 1.6364
rs73115423 [TT] 151 107 40 135
[TA] 10 4 6 7
[AA] 0 0 0 0
[T] frequency 0.9936 0.9820 0.9348 0.9754
[A] frequency 0.0064 0.0180 0.0652 0.0246
Odds ratio test results – comparisons between studied groups
1 versus 4 2 versus 4 3 versus 4 2 versus 3
p-value 0.6343 0.6132 0.0748 0.0424
Odds ratio value 0.7884 1.3773 0.3622 3.8023

An analysis of clinical parameters performed according to detected polymorphisms among children with short stature presented no significant differences in terms of hSDS, peak GH level, as well as growth velocity in the first year of rhGH therapy for both variants. However, it is worth mentioning that for rs73115423, the difference in peak GH levels between TT and TA was close to statistical significance, with higher values in TA patients (p = 0.060), as shown in Table 3.

Table 3.

Clinical characteristics of children with short stature, performed according to detected polymorphisms

Children with short stature
rs3834468 rs73115423

[-/-]

n = 148

[-/insG]

n = 8

[insG/insG]

n = 1

p-value**

[TT]

n = 147

[TA]

n = 10

p-value
gender F 38 (90.5%)

3

(7.1%)

1

(2.4%)

0.192

41

(97.6%)

1

(2.4%)

0.216
M

110

(95.7%)

5

(4.3%)

0

(0.0%)

106

(92.2%)

9

(7.8%)

hSDS

−2.79

± 0.71

−2.79

± 0.29

−2.80

-

0.441

−2.78

± 0.70

−2.91

± 0.65

0.376
Peak GH

9.00

± 5.07

7.90

± 5.81

13.9

-

0.449

8.72

± 4.83

12.87

± 7.25

0.060
Growth velocity*

8.94

± 1.29

8.85

± 1.32

- 0.716

8.97

± 1.29

8.25

± 1.14

0.231

hSDS, height standard deviation score; Peak GH, peak growth hormone serum level in stimulation tests; Growth velocity, height increment in centimeters during in the first year of rhGH treatment; [-/-], wild type genotype; *data available for 89 patients; **insG/insG group excluded from comparison because of only one variable

In the control group, there was a significant difference in hSDS for rs3834468 between children with wild type genotype (wt, [-/-]) and heterozygotes [-/insG] (p = 0.003). Higher hSDS values were found in those carrying insG allele. However, as regarding the group of heathy children only in boys this variant was observed, we have made additional analysis separately for male gender, which confirmed observed differences (p = 0.002). No significant differences were found in hSDS for rs73115423 between TT and TA individuals (Table 4).

Table 4.

Clinical characteristics of healthy children from the control group, performed according to detected polymorphisms

Healthy children of normal height
rs3834468 rs73115423

[-/-]

n = 138

[-/insG]

n = 4

[insG/insG]

n = 0

p-value

[TT]

n = 135

[TA]

n = 7

p-value
gender F 63 (100.0%)

0

(0.0%)

0

(0.0%)

0.070

58

(92.1%)

5

(7.9%)

0.139
M

75

(94.9%)

4

(5.1%)

0

(0.0%)

77

(97.5%)

2

(2.5%)

hSDS

0.24

± 0.93

1.72

± 0.23

- 0.003

0.29

± 0.96

0.00

± 0.85

0.399

hSDS, height standard deviation score; [-/-], wild type genotype

Discussion

The human HMGA2 gene has 5 exons and 4 introns and is located on chromosome 12 (12q14.3) (Su et al. 2020). It encodes a small multipotential nuclear protein, the mammalian high-mobility group protein AT-hook2, which belongs to the non-histone chromosomal high-mobility group (HMG). HMGA2 is well conserved in mammals, as the protein sequences in humans and mice are almost identical. Its structure contains 3 “AT-hook” DNA-binding motifs and a negatively charged C-terminal motif. The “AT-hook” motifs specifically bind to the minor groove of AT-rich DNA and induce DNA bending. It has been hypothesized that HMGA2 may function as an architectural transcription factor or an epigenetic regulator (Su et al. 2020; Lee et al. 2022). It appears to affect diverse biological processes, as it interacts with numerous proteins, primarily transcriptional factors, and is involved in the regulation of various genes (Lee et al. 2022). Human and animal studies have reported its high expression during embryogenesis and fetal development, but hardly detectable expression levels in adult tissues (Gorbenko del Blanco et al. 2011; Mercandante et al. 2020). The main functions of HMGA2 are likely related to promoting cell proliferation and differentiation and maintaining the potency of stem cells (Su et al. 2020; Lee et al. 2022). HMGA2 has been linked to diverse processes, including linear growth, adiposity, and tumorigenesis. Overexpression or aberrant expression of HMGA2 is linked to the development and progression of various tumors (benign or malignant), including lung, breast, prostate, or gastric cancers, as well as melanoma or leukemia (Su et al. 2020; Lee et al. 2022; Mercandante et al. 2020).

The HMGA2 gene became a candidate for longitudinal growth regulation as rare severe mutations in this gene alter body size in various species, including mice and humans (Grant et al. 2008; Yang et al. 2010). In murine studies, it has been demonstrated that homozygous deletion leads to dwarfism (Hendriks et al. 2011; Lee et al. 2022).

An essential role of HMGA2 in human height regulation is supported by observations of patients with microdeletion of chromosomal region 12q14, who exhibit similar symptoms, including failure to thrive, short stature, and developmental delay. Severe growth restriction in these patients is thought to be a consequence of HMGA2 gene loss, as it lies within this particular region (Fusco et al. 2016; Lynch et al. 2011). This theory was supported by Buysse et al. (2009), who described a case of submicroscopic intragenic deletion disrupting only HMGA2 in a child with proportionate short stature as an isolated symptom with no other abnormalities. In this case, a cosegregation of this deletion in the child’s family was related to reduced adult height. HMGA2 was also proposed to be included as a candidate gene in Silver-Russel syndrome (SRS) molecular background. Apart from prenatal and postnatal growth failure, this syndrome is additionally related to certain dysmorphic features, like macrocephaly at birth, protruding forehead, or body asymmetry (Mercandante et al. 2020). However, if an effect on expression is low, it could also cause growth restrictions without other symptoms.

More data on the importance of the HMGA2 gene for growth in the general population has been obtained from genome-wide association studies (GWAS). It has been shown that HMGA2 gene variants affect height outcomes in both adults and children. Namely, the rs1042725 variant localized in the 3’ untranslated region (UTR) explains approximately 0.3% of population height variation with an increase of 0.4–0.9 cm in adult height (Weedon et al. 2007, 2008; Yang et al. 2010). In the study of Weedon et al. (2007), this variant was also strongly associated with height in children at the age of 7, 9, 10, and 11. The overall effect was assessed as approximately 0.4 cm increase in the C allele carriers. In the same paper, limb length was also related to the rs1042725 variant, suggesting an impact on the general skeletal longitudinal growth. However, no association was found with the birth length.

Yang et al. (2010), have confirmed the association of the HMGA2 gene with adult human height using data from approx. 11,000 subjects, including Caucasian and Chinese origin, which points to this gene’s importance for height across ethnic boundaries.

It has been shown that, along with the role in determining variability in human height, HMGA2 variants may contribute to susceptibility to idiopathic short stature. It also seems to be involved in the regulation of GH/IGF1 and IGF2 axis (Toni et al. 2024). A known target gene for HMGA2 is IGF2BP2, encoding insulin-like growth factor 2 mRNA-binding protein. IGF2BP2, in turn is engaged in the post-transcriptional regulation of IGF2, one of the important fetal growth factors (Gorbenko del Blanco et al. 2011). Moreover, in some patients with 12q14 microdeletion syndrome, low GH levels were detected (Lynch et al. 2011), while Gorbenko del Blanco et al. (2011), in their research, reported a deletion in the HMGA2 gene that might be related to isolated GHD.

As GH is crucial for normal growth in children, its deficiency usually results in short stature. However, GH is considered to affect the postnatal stage of human growth and children with isolated GHD are typically born with normal weight (Toni et al. 2024). Still, a child born small for gestational age (SGA) may additionally present decreased GH serum levels and fulfill the criteria of GHD.

It is important to note that an endocrine diagnosis of GHD carries a risk of ambiguity, as diagnostic criteria are not uniform across countries. Appropriate peak GH cut-off levels remain a matter of discussion and vary between 5 and 10 ng/ml (Hage et al. 2021). In Poland, deficient GH secretion is diagnosed below 10 ng/ml, while in many countries lower values are used. Furthermore, GHD can be defined as partial with a peak serum GH concentration between 5 and 10 ng/ml, or severe with a GH level below 5 or according to other authors below 3 ng/ml (Majewska et al. 2024; Binder et al. 2019; Allen 2021; Collett-Solberg et al. 2019; Murray et al. 2016; Webb and Dattani 2010; Grimberg et al. 2016). Therefore, due to the above considerations, for the purposes of the study, we used various options for dividing the study group depending on peak GH levels, including additional ranges below 5 and between 5 and 10 ng/ml.

The incidence of congenital form of GHD ranges from 1 in 4000 to 1 in 10,000 live births. Possible causes include genetic factors or structural changes in the area of the hypothalamus and pituitary gland, but most cases are classified as idiopathic. Familial occurrence of GHD concerns 3% to 30% of cases, suggesting a genetic background (Grunauer and Jorge 2018; Hage et al. 2021; Alatzoglou et al. 2014). Mutations in genes encoding growth hormone (GH1) and the receptor for growth hormone-releasing factor (GHRHR) have been proven to cause GHD. However, in the vast majority of patients, these mutations are not detected. Also, in our previous study, where we investigated the GH1 gene in Polish children with short stature and GHD, we did not find it to be a frequent causative factor (Majewska et al. 2020). That, in turn, suggests the involvement of other genes in GHD pathogenesis (Gorbenko del Blanco et al. 2011).

Although the HMGA2 gene’s relation to height regulation seems to be confirmed, its associations with idiopathic short stature or GHD are only suspected. In this research, we compared a cohort of Polish children with short stature to healthy children of normal height. We did not find any sequence variant in the assessed coding region of the HMGA2 gene. Nonetheless, in the flanking intronic sequences of exon 3, we detected two polymorphic variants: rs3834468 and rs73115423. We observed the lack of significant differences in allele frequencies between all patients and controls in both polymorphic sites, which would suggest that the HMGA2 gene is irrelevant in the pathogenesis of short stature in the Polish population. However, a detailed analysis among children with short stature, based on various growth hormone peak serum levels, showed a significant difference in the frequency of the rs73115423 variant between children with normal growth hormone secretion and those with moderate GHD, while differences with the lowest GH secretion did not reach statistical significance. This observation suggests that HMGA2 may be involved in complex mechanisms of GH secretion regulation. The other detected variant, rs3834468, presented no statistically significant results among short stature children, but in the control group, a significant difference was found in terms of hSDS. Children with a heterozygous genotype for the G insertion appeared to be significantly taller than subjects carrying wild type genotype. We may hypothesize this variant to be height-increasing in healthy populations, which has not been described in previous reports. However, our observation was made based on a relatively small number of patients; therefore, confirmation would require further research with a substantially increased cohort of healthy individuals.

Observed intronic variants may affect protein structure and function if they interfere with the normal pre-mRNA splicing process or are in the linkage disequilibrium with another sequence alteration that may influence the protein integrity and function. Moreover, genetic variants within intronic regions may impact regulatory elements, including enhancers and silencers, that are situated in these non-coding sequences (Wrighton 2017). In relation to growth, a known example of an intron-located functional polymorphism was identified in the GH1 gene (the rs2665802 A > T in position + 1169; intron 4). Functional assays revealed that the + 1169 A allele is directly associated with reduced GH1 expression and GH secretion, despite not affecting coding sequences. This variant has been linked to lower circulating GH and IGF-1 levels, as well as altered disease risks for e.g., colorectal cancer, osteoporosis (Millar et al. 2010). These findings highlight the underappreciated role of intronic regulatory elements, which may harbor functional variants influencing splicing, enhancers, and long-range regulation. Such intron-based polymorphisms should thus be given greater consideration in genetic studies.

Diagnostic process in children with growth retardation is complex, multidirectional, and time-consuming. At the same time, the results obtained are not always unambiguous, and the final decision is often a judgment call depending on the experience of the specialist taking care of the patient (Allen 2021). Hence, it is reasonable to search for methods that enable a quick and accurate diagnosis, and at the same time enable the selection of the most appropriate treatment. Precise determination of the genetic causes of short stature in children could potentially help to reduce certain burdensome examinations carrying the risk of complications, such as GH stimulation tests. It could also help to predict the possible effectiveness of available therapies such as rhGH (Vasques et al. 2019). Treatment with rhGH is considered safe and effective, but requires long-term adherence and is cost-consuming, while the degree of therapeutic response differs across patients.

Among the limitations of our study, it is worth noting that GH serum concentrations were evaluated only in children with short stature. Since stimulation tests could not be performed in healthy children from the control group, the assumption of normal GH secretion in these children was based on their normal height, appropriate for their age and sex. Another issue that should be addressed is the disproportion in gender distribution within the study group. Male predominance among patients with short stature is a common observation, consistently reported in studies worldwide and confirmed in our previous research (Collett-Solberg et al. 2019; Grimberg et al. 2008; Majewska et al. 2020, 2024). However, this is not due to a generally higher incidence of short stature in boys, as the diagnosis is established in both genders according to similar criteria, when height is below − 2 SD from the mean for age and gender. By this definition, approximately 2.5% of both girls and boys meet the criteria for short stature. Nevertheless, among patients, i.e., children who are referred for diagnostics, boys commonly predominate. It is assumed to be a consequence of greater social acceptance of shorter stature in girls, whereas there is a greater social expectation for taller stature in boys. This, in turn, may lead to boys being more frequently referred to specialist centers, while girls are more often left undiagnosed, even though they should also be appropriately evaluated and treated (Grimberg et al. 2008; Majewska et al. 2020, 2024).

Conclusions

Our findings do not support a definitive role of the HMGA2 gene in the pathogenesis of short stature in the Polish pediatric population. However, they suggest a potential involvement of this gene in the complex mechanisms regulating the somatotropic axis. Although no coding variants of HMGA2 were identified, the analysis of detected intronic polymorphisms suggests a possible influence on growth hormone secretion. Further studies involving larger cohorts are needed to clarify the functional significance of HMGA2 variants in human growth processes.

Supplementary Information

Below is the link to the electronic supplementary material.

Funding

This study was financed by the Department of Pediatric Diabetes, Auxology and Obesity, Poznan University of Medical Sciences, Poland and supported by the Institute of Human Genetics, Polish Academy of Sciences.

Data availability

Data analyzed during this study are available from the corresponding author upon a reasonable request.

Declarations

Competing interests

The authors declare no conflict of interest.

Ethics approval

This study was conducted in accordance with the principles of the Declaration of Helsinki and based on the approval of the local Ethics Committee at Poznan University of Medical Sciences (No. 1070/15).

Consent to participate

Informed consent was obtained from legal guardians of all participants included in the study.

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. Alatzoglou KS, Webb EA, Le Tissier P, Dattani MT (2014) Isolated growth hormone deficiency (GHD) in childhood and adolescence: recent advances. Endocr Rev 35:376–432. 10.1210/er.2013-1067 [DOI] [PubMed] [Google Scholar]
  2. Allen DB (2021) Diagnosis of growth hormone deficiency remains a judgment call - and that is good. Horm Res Paediatr 94:406–409. 10.1159/000521628 [DOI] [PubMed] [Google Scholar]
  3. Bang P (2024) Pediatric implications of normal Insulin-GH-IGF axis physiology. In: Feingold KR, Ahmed SF, Anawalt B et al (eds) Endotext. South Dartmouth (MA). MDText.com, Inc. [PubMed]
  4. Bicknell LS, Hirschhorn JN, Savarirayan R (2025) The genetic basis of human height. Nat Rev Genet 26:604–619. 10.1038/s41576-025-00834-1 [DOI] [PubMed] [Google Scholar]
  5. Binder G, Reinehr T, Ibáñez L et al (2019) GHD diagnostics in Europe and the US: an audit of National guidelines and practice. Horm Res Paediatr 92:150–156. 10.1159/000503783 [DOI] [PubMed] [Google Scholar]
  6. Buysse K, Reardon W, Mehta L et al (2009) The 12q14 microdeletion syndrome: additional patients and further evidence that HMGA2 is an important genetic determinant for human height. Eur J Med Genet 52:101–107. 10.1016/j.ejmg.2009.03.001 [DOI] [PubMed] [Google Scholar]
  7. Collett-Solberg PF, Ambler G, Backeljauw PF et al (2019) Diagnosis, genetics, and therapy of short stature in children: a growth hormone research society international perspective. Horm Res Paediatr 92:1–14. 10.1159/000502231 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fusco I, Babu D, Mellone S et al (2016) Variations in the high-mobility group-A2 gene (HMGA2) are associated with idiopathic short stature. Pediatr Res 79:258–261. 10.1038/pr.2015.225 [DOI] [PubMed] [Google Scholar]
  9. Gorbenko del Blanco D, de Graaff LC, Posthouwer D, Visser TJ, Hokken-Koelega AC (2011) Isolated GH deficiency: mutation screening and copy number analysis of HMGA2 and CDK6 genes. Eur J Endocrinol 165:537–544. 10.1530/EJE-11-0478 [DOI] [PubMed] [Google Scholar]
  10. Grant SFA, Li M, Bradfield JP et al (2008) Association of HMGA2 gene variation with height in specific pediatric age categories. Genomics Insights. 10.4137/GEI.S944 [DOI] [Google Scholar]
  11. Grimberg A, DiVall SA, Polychronakos C et al (2016) Guidelines for growth hormone and Insulin-Like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary Insulin-Like growth factor-I deficiency. Horm Res Paediatr 86:361–397. 10.1159/000452150 [DOI] [PubMed] [Google Scholar]
  12. Grimberg A, Stewart E, Wajnrajch MP (2008) Gender of pediatric recombinant human growth hormone recipients in the united states and globally. J Clin Endocrinol Metab 93:2050–2056. 10.1210/jc.2007-2617 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Grunauer M, Jorge AAL (2018) Genetic short stature. Growth Horm IGF Res 38:29–33. 10.1016/j.ghir.2017.12.003 [DOI] [PubMed] [Google Scholar]
  14. Hage C, Gan HW, Ibba A, Patti G, Dattani M, Loche S, Maghnie M, Salvatori R (2021) Advances in differential diagnosis and management of growth hormone deficiency in children. Nat Rev Endocrinol 17:608–624. 10.1038/s41574-021-00539-5 [DOI] [PubMed] [Google Scholar]
  15. Hendriks AE, Brown MR, Boot AM, Oostra BA, Drop SL, Parks JS (2011) Genetic variation in candidate genes like the HMGA2 gene in the extremely tall. Horm Res Paediatr 76:307–313. 10.1159/000330764 [DOI] [PubMed] [Google Scholar]
  16. Kułaga Z, Grajda A, Gurzkowska B et al (2013) Polish 2012 growth references for preschool children. Eur J Pediatr 172:753–761. 10.1007/s00431-013-1954-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kułaga Z, Litwin M, Tkaczyk M et al (2011) Polish 2010 growth references for school-aged children and adolescents. Eur J Pediatr 170:599–609. 10.1007/s00431-010-1329-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lee MO, Li J, Davis BW et al (2022) Hmga2 deficiency is associated with allometric growth retardation, infertility, and behavioral abnormalities in mice. G3 (Bethesda) 12:jkab417. 10.1093/g3journal/jkab417 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lynch S, Foulds N, Thuresson AC et al (2011) The 12q14 microdeletion syndrome: six new cases confirming the role of HMGA2 in growth. Eur J Hum Genet 19:534–539. 10.1038/ejhg.2010.215 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Majewska KA, Kedzia A, Kontowicz P, Prauzinska M, Szydlowski J, Switonski M, Nowacka-Woszuk J (2020) Polymorphism of the growth hormone gene GH1 in Polish children and adolescents with short stature. Endocrine 69:157–164. 10.1007/s12020-020-02305-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Majewska KA, Tchorzewska-Skrobich M, Wais P, Majewski D, Naskręcka M, Kędzia A (2024) Deficient or normal growth hormone secretion in Polish children with short stature: searching for clinical differences. Biomedicines 12:1673. 10.3390/biomedicines12081673 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mercadante F, Busè M, Salzano E, Fragapane T, Palazzo D, Malacarne M, Piccione M (2020) 12q14.3 microdeletion involving HMGA2 gene cause a Silver-Russell syndrome-like phenotype: a case report and review of the literature. Ital J Pediatr 46:108. 10.1186/s13052-020-00866-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Millar DS, Horan M, Chuzhanova NA, Cooper DN (2010) Characterisation of a functional intronic polymorphism in the human growth hormone (GH1) gene. Hum Genomics 4:289–301. 10.1186/1479-7364-4-5-289 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Murray PG, Dattani MT, Clayton PE (2016) Controversies in the diagnosis and management of growth hormone deficiency in childhood and adolescence. Arch Dis Child 101:96–100. 10.1136/archdischild-2014-307228 [DOI] [PubMed] [Google Scholar]
  25. Oświęcimska J, Roczniak W, Mikołajczak A, Szymlak A (2016) Growth hormone deficiency in children and young adults. Postepy Hig Med Dosw 70:928–937. 10.5604/17322693.1218181 [DOI] [PubMed] [Google Scholar]
  26. Palczewska I, Niedzwiedzka Z (2001) Somatic development indices in children and youth of Warsaw. Med Wieku Rozwoj 5:18–118 [PubMed] [Google Scholar]
  27. Su L, Deng Z, Leng F (2020) The mammalian high mobility group protein AT-Hook 2 (HMGA2): biochemical and biophysical properties, and its association with adipogenesis. Int J Mol Sci 21:3710. 10.3390/ijms21103710 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Toni L, Plachy L, Dusatkova P et al (2024) The genetic landscape of children born small for gestational age with persistent short stature. Horm Res Paediatr 97:40–52. 10.1159/000530521 [DOI] [PubMed] [Google Scholar]
  29. Untergasser A, Cutcutache I, Koressaar T et al (2012) Primer 3 - new capabilities and interfaces. Nucleic Acids Res 40:e115. 10.1093/nar/gks596 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Vasques GA, Andrade NLM, Jorge AAL (2019) Genetic causes of isolated short stature. Arch Endocrinol Metab 63:70–78. 10.20945/2359-3997000000105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Webb EA, Dattani MT (2010) Diagnosis of growth hormone deficiency. Endocr Dev 18:55–66. 10.1159/000316127 [DOI] [PubMed] [Google Scholar]
  32. Weedon MN, Lango H, Lindgren CM et al (2008) Genome-wide association analysis identifies 20 loci that influence adult height. Nat Genet 40:575–583. 10.1038/ng.121 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Weedon MN, Lettre G, Freathy RM et al (2007) A common variant of HMGA2 is associated with adult and childhood height in the general population. Nat Genet 39:1245–1250. 10.1038/ng2121 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Wit JM, Deeb A, Bin-Abbas B, Al Mutair A, Koledova E, Savage MO (2019) Achieving optimal short- and long-term responses to paediatric growth hormone therapy. J Clin Res Pediatr Endocrinol 11(4):329–340. 10.4274/jcrpe.galenos.2019.2019.0088 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wrighton KH (2017) Transcription: intragenic enhancers dampen gene expression. Nat Rev Mol Cell Biol 18:714–715. 10.1038/nrm.2017.111 [DOI] [PubMed] [Google Scholar]
  36. Yang TL, Guo Y, Zhang LS et al (2010) HMGA2 is confirmed to be associated with human adult height. Ann Hum Genet 74:11–16. 10.1111/j.1469-1809.2009.00555.x [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Data Availability Statement

Data analyzed during this study are available from the corresponding author upon a reasonable request.


Articles from Journal of Applied Genetics are provided here courtesy of Springer

RESOURCES